prikaz prve stranice dokumenta Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
  Download
PDF 3.06 MB
Scientific paper - Original scientific paper
Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
Frontiers in Immunology, 13 (2022); 816159. https://doi.org/10.3389/fimmu.2022.816159
Ravlić, Sanda; Hećimović, Ana; Kurtović, Tihana; Ivančić Jelečki, Jelena; Forčić, Dubravko; Slović, Anamarija; Kurolt, Ivan Christian; Mačak Šafranko, Željka; Mušlin, Tatjana; Rnjak, Dina; Jakšić, Ozren; Sorić, Ena; Džepina, Gorana; Đaković Rode, Oktavija; Kujavec Šljivac, Kristina; Vuk, Tomislav; Jukić, Irena; Markotić, Alemka; Halassy, Beata More authors...

Linked objects
COVID-19 | Virtual collection
Cite this document

Ravlić, S., Hećimović, A., Kurtović, T., Ivančić Jelečki, J., Forčić, D., Slović, A. ... Halassy, B. (2022). Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?. Frontiers in Immunology, 13.. doi: 10.3389/fimmu.2022.816159

Ravlić, Sanda, et al. "Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?." Frontiers in Immunology, vol. 13, 2022. https://doi.org/10.3389/fimmu.2022.816159

Ravlić, Sanda, Ana Hećimović, Tihana Kurtović, Jelena Ivančić Jelečki, Dubravko Forčić, Anamarija Slović, Ivan Christian Kurolt, et al. "Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?." Frontiers in Immunology 13 (2022). https://doi.org/10.3389/fimmu.2022.816159

Ravlić, S., et al. (2022) 'Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?', Frontiers in Immunology, 13. doi: 10.3389/fimmu.2022.816159

Ravlić S, Hećimović A, Kurtović T, Ivančić Jelečki J, Forčić D, Slović A, and sur.. Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?. Frontiers in Immunology [Internet]. 2022 [cited 2024 December 21];13. doi: 10.3389/fimmu.2022.816159

S. Ravlić, et al., "Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?", Frontiers in Immunology, vol. 13, 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:917926. [Accessed: 21 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
AuthorSanda Ravlić
MBZ: 305793
AuthorAna Hećimović
MBZ: 217216
AuthorTihana Kurtović
MBZ: 309540
AuthorJelena Ivančić Jelečki
MBZ: 238350
AuthorDubravko Forčić
MBZ: 211105
AuthorAnamarija Slović
MBZ: 380153
AuthorIvan Christian Kurolt
MBZ: 302106
AuthorŽeljka Mačak Šafranko
MBZ: 268386
AuthorTatjana Mušlin
AuthorDina Rnjak
AuthorOzren Jakšić
MBZ: 238451
AuthorEna Sorić
AuthorGorana Džepina
AuthorOktavija Đaković Rode
MBZ: 261522
AuthorKristina Kujavec Šljivac
AuthorTomislav Vuk
MBZ: 361422
AuthorIrena Jukić
MBZ: 341464
AuthorAlemka Markotić
AuthorBeata Halassy
MBZ: 223834
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
During the ongoing COVID-19 epidemic many efforts have gone into the investigation of the SARS-CoV-2–specific antibodies as possible therapeutics. Currently, conclusions cannot be drawn due to the lack of standardization in antibody assessments. Here we describe an approach of establishing antibody characterisation in emergent times which would, if followed, enable comparison of results from different studies. The key component is a reliable and reproducible assay of wild-type SARS-CoV-2 neutralisation based on a banking system of its biological components - a challenge virus, cells and an anti- SARS-CoV-2 antibody in-house standard, calibrated to the First WHO International Standard immediately upon its availability. Consequently, all collected serological data were retrospectively expressed in an internationally comparable way. The neutralising antibodies (NAbs) among convalescents ranged from 4 to 2869 IU mL-1 in a significant positive correlation to the disease severity. Their decline in convalescents was on average 1.4-fold in a one-month period. Heat-inactivation resulted in 2.3-fold decrease of NAb titres in comparison to the native sera, implying significant complement activating properties of SARS-CoV-2 specific antibodies. The monitoring of NAb titres in the sera of immunocompromised COVID-19 patients that lacked their own antibodies evidenced the successful transfusion of antibodies by the COVID-19 convalescent plasma units with NAb titres of 35 IU mL-1 or higher.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleFrontiers in Immunology
Numberingvol. 13, 816159
e-ISSN1664-3224
DOIhttps://doi.org/10.3389/fimmu.2022.816159
URN:NBNurn:nbn:hr:184:917926
Publication2022
ProjectNumber: KK.011.1.01.0006
Title (croatian): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Leader: Stipan Jonjić
Jurisdiction: eu
ProjectNumber: IP-CORONA-2020-04-2053
Title (croatian): Stvaranje preduvjeta za uvođenje SARS-CoV-2 seroterapije u Hrvatskoj
Leader: Beata Halassy
Jurisdiction: Croatia
Funding stream: IP-CORONA
ProjectNumber: N/A
Title (croatian): Centar izvrsnosti za virusnu imunologiju i cjepiva
Title (english): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Acronym: CERVirVac
Leader: Stipan Jonjić
Jurisdiction: Croatia
Funding stream: ZCI
Document URLhttp://bib.irb.hr/1183053
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-03-23 11:02:26